Literature DB >> 29458693

The Impact of Continuous Positive Airway Pressure on Circulating IGF-1 in Patients With Obstructive Sleep Apnea.

Andreas Palm1,2, Christian Berne3, Helena Igelström4, Pernilla Åsenlöf4, Christer Janson1, Eva Lindberg1.   

Abstract

STUDY
OBJECTIVES: Obstructive sleep apnea (OSA) is a disease with metabolic and cardiovascular consequences and is associated with decreased serum concentrations of insulin-like growth factor-1 (IGF-1). The aim of this study was to investigate whether continuous positive airway pressure (CPAP) will increase serum IGF-1 concentration in patients with OSA.
METHODS: Patients with moderate to severe OSA were recruited from a sleep clinic and serum IGF-1 was measured before initiation of CPAP and at follow-up after 4.8 ± 2.5 months. Patients adherent to CPAP treatment (usage ≥ 4 h/night) were compared with those considered to be nonadherent (usage < 4 h/night).
RESULTS: Complete data were obtained from 69 patients (86% male, age 56 ± 12 years, respiratory event index 43 ± 21 events/h, Epworth Sleepiness Scale score 12 ± 5). In those adherent to CPAP (n = 42), there was an increase in serum IGF-1 concentration with 21.1 (95% confidence interval [CI]: 13.1 to 29.2) μg/L compared to 4.7 (95% CI: -4.1 to 13.5) μg/L in the nonadherent group (n = 27) (P = .0083). In a linear multivariate model adjusting for sex, age, body mass index, respiratory event index, and mean oxygen saturation during the night recording, the change in serum IGF-1 concentration was significantly associated with adherence to CPAP treatment (adjusted β coefficient: 21.8, 95% CI: 10.2 to 33.4) and inversely associated with change in body mass index (adjusted β coefficient: -7.1, 95% CI: -11.3 to -3.0) and change in hemoglobin A1c (adjusted β coefficient: -1.8, 95% CI: -33 to -0.3).
CONCLUSIONS: CPAP usage ≥ 4 h/night is associated with increased serum IGF-1 concentration in male patients with OSA.
© 2018 American Academy of Sleep Medicine.

Entities:  

Keywords:  IGF-1; adherence; continuous positive airway pressure; obstructive sleep apnea

Mesh:

Substances:

Year:  2018        PMID: 29458693      PMCID: PMC5837839          DOI: 10.5664/jcsm.6982

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  36 in total

Review 1.  Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.

Authors: 
Journal:  Sleep       Date:  1999-08-01       Impact factor: 5.849

Review 2.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

3.  CPAP treatment of a population-based sample--what are the benefits and the treatment compliance?

Authors:  Eva Lindberg; Christian Berne; Ahmed Elmasry; Jan Hedner; Christer Janson
Journal:  Sleep Med       Date:  2006-06-05       Impact factor: 3.492

4.  Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study.

Authors:  Aletta E Schutte; Elena Conti; Catharina Mc Mels; Wayne Smith; Ruan Kruger; Shani Botha; Lucio Gnessi; Massimo Volpe; Hugo W Huisman
Journal:  Eur J Prev Cardiol       Date:  2016-07-22       Impact factor: 7.804

5.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

6.  Physiology of growth hormone secretion during sleep.

Authors:  E Van Cauter; L Plat
Journal:  J Pediatr       Date:  1996-05       Impact factor: 4.406

Review 7.  Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome.

Authors:  Luciano F Drager; Sônia M Togeiro; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho
Journal:  J Am Coll Cardiol       Date:  2013-06-12       Impact factor: 24.094

8.  The effect of CPAP therapy on insulin-like growth factor and cognitive functions in obstructive sleep apnea patients.

Authors:  Asiye Kanbay; Neslihan Cerrah Demir; Nuri Tutar; Osman Köstek; Zuhal Özer Şimşek; Hakan Buyukoglan; Ramazan Demir; Liborio Parrino
Journal:  Clin Respir J       Date:  2015-09-15       Impact factor: 2.570

9.  Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis.

Authors:  Imran H Iftikhar; Christopher W Valentine; Lia R A Bittencourt; Debbie L Cohen; Annette C Fedson; Thorarinn Gíslason; Thomas Penzel; Craig L Phillips; Lin Yu-sheng; Allan I Pack; Ulysses J Magalang
Journal:  J Hypertens       Date:  2014-12       Impact factor: 4.844

10.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  3 in total

Review 1.  Effects of telemedicine interventions in improving continuous positive airway pressure adherence in patients with obstructive sleep apnoea: a meta-analysis of randomised controlled trials.

Authors:  Yuli Hu; Yijia Su; Jun Ma; Sanlian Hu; Zuoyan Zhang; Fang Fang; Jian Guan
Journal:  Sleep Breath       Date:  2021-03-10       Impact factor: 2.816

2.  The Somatotropic Axis in the Sleep Apnea-Obesity Comorbid Duo.

Authors:  Louis-Marie Galerneau; Anne-Laure Borel; Olivier Chabre; Marc Sapene; Bruno Stach; Janie Girey-Rannaud; Renaud Tamisier; Jean-Louis Pépin; Philippe Caron
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-12       Impact factor: 5.555

3.  Serum concentrations of insulin-like growth factor-1 as a biomarker of improved circadian rhythm sleep-wake disorder in school-aged children.

Authors:  Shigemi Kimura; Makiko Toyoura; Yuko Toyota; Yutaka Takaoka
Journal:  J Clin Sleep Med       Date:  2020-12-15       Impact factor: 4.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.